What’s Propelling Cytori Therapeutics, Inc. (CYTX) to Decrease? The Stock Formed a Bearish Multiple Bottom Chart Pattern

January 13, 2018 - By Peter Erickson

The stock of Cytori Therapeutics, Inc. (CYTX) shows a multiple bottoms pattern with $0.34 target or 5.00 % below today’s $0.35 share price. The 7 months chart pattern indicates high risk for the $12.43M company. It was reported on Jan, 13 by Finviz.com. If the $0.34 price target is reached, the company will be worth $621,600 less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 7.01% or $0.027 during the last trading session, reaching $0.354. About 1.92M shares traded or 64.42% up from the average. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 65.60% since January 13, 2017 and is downtrending. It has underperformed by 82.30% the S&P500.

Analysts await Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report earnings on March, 22. They expect $-0.07 earnings per share, up 70.83 % or $0.17 from last year’s $-0.24 per share. After $-0.14 actual earnings per share reported by Cytori Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -50.00 % EPS growth.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Coverage

Among 6 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Cytori Therapeutics has $1000 highest and $0.5 lowest target. $3.35’s average target is 846.33% above currents $0.354 stock price. Cytori Therapeutics had 11 analyst reports since August 8, 2015 according to SRatingsIntel. Zacks upgraded the stock to “Hold” rating in Friday, September 4 report. The firm has “Buy” rating by TH Capital given on Monday, August 10. The company was maintained on Monday, July 24 by Maxim Group. The stock has “Neutral” rating by B. Riley & Co on Tuesday, July 25. Maxim Group maintained the shares of CYTX in report on Saturday, August 8 with “Buy” rating. Maxim Group maintained Cytori Therapeutics, Inc. (NASDAQ:CYTX) rating on Monday, July 10. Maxim Group has “Buy” rating and $1000 target. The firm has “Buy” rating by Maxim Group given on Friday, August 11. Maxim Group maintained it with “Buy” rating and $1000 target in Wednesday, May 31 report.

More recent Cytori Therapeutics, Inc. (NASDAQ:CYTX) news were published by: Marketwatch.com which released: “Cytori Therapeutics’ stock plunges toward record low after stock offering …” on April 11, 2017. Also Seekingalpha.com published the news titled: “Cytori Therapeutics jumps as Maxim sees it as takeover candidate” on January 05, 2018. Seekingalpha.com‘s news article titled: “Cytori Therapeutics’ (CYTX) CEO Marc Hedrick on Q3 2017 Results – Earnings …” with publication date: November 10, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: